Aarti Pharmalabs Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹386Cr
- −30.5% YoY
- −31.6% QoQ
- Net profit
- ₹50Cr
- −9.1% YoY
- −43.2% QoQ
- Margin
- 24%
- +7 pp YoY
- −2 pp QoQ
Guidance rank: #5 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Aarti Pharmalabs Ltd Q1 FY26 key numbers
- Revenue
- CDMO segment expected to grow 30%-40% this year, aiming for Rs. 800-1,000 crores revenue in 3-4 years.
As stated in Aarti Pharmalabs Ltd's Q1 FY26 earnings call transcript · published 5 Aug 2026. Reported figures, not investment advice.
The short version
CDMO segment expected to grow 30%-40% this year, aiming for Rs. 800-1,000 crores revenue in 3-4 years (Page 17, 9). CDMO segment is expected to grow at 30%-40% annually this year, aiming for Rs. 800-1000 crore revenue in 3-4 years.
From Aarti Pharmalabs Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CDMO segment expected to grow 30%-40% this year, aiming for Rs. 800-1,000 crores revenue in 3-4 years (Page 17, 9).
- Overall CDMO growth target of Rs. 800-1,000 crores by FY '29 (Page 9).
- Xanthine business capacity expanding from 5,000 to 9,000 tons, targeting Rs. 1,000+ crores revenue in 2-3 years with 80%-90% utilization and 50% of sales to beverages and regulated customers (Pages 10-11).
- API segment expected to grow 10%-15% this year and maintain reasonable growth levels, with capacity expansions and de-bottlenecking underway (Page 17).
2 more points from Aarti Pharmalabs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Brownfield expansion to increase Xanthine derivatives capacity from 5,000 MT to 9,000 MT per annum; commissioning to be done in a phased manner across H2 FY '26.
- Greenfield project at Atali, Gujarat nearing completion; mechanical completion of Phase-1 achieved; commercial production to commence towards end of Q2 FY '26.
- Additional caffeine capacity addition planned in second half of this year.
- Next year to see higher capacities enabling production of more products.
- Ongoing efforts on de-bottlenecking of API lines and capacity additions to support growth in base business.
2 more points from Aarti Pharmalabs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company currently has an order book guiding CDMO sales growth of 35%-40% for the year.
- There are 60 ongoing active CDMO projects: 33 in commercial stages and 27 in different stages of development.
- The management is confident about achieving Rs. 800 crore to Rs. 1,000 crore revenue from the CDMO segment by FY '28 or FY '29, a 3-4 year timeline.
- Growth drivers include both existing commercial molecules and a robust underdevelopment pipeline.
2 more points from Aarti Pharmalabs Ltd's call on order book
Create a free account to keep reading this call
Aarti Pharmalabs Ltd — Quarterly revenue & net profit
Aarti Pharmalabs Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 386 | 555 | -30.5% | 564 | -31.6% |
| Operating profit (EBITDA) | 93 | 96 | -3.1% | 146 | -36.3% |
| Operating margin | 24% | 17% | +7 pp | 26% | -2 pp |
| Profit before tax | 65 | 74 | -12.2% | 115 | -43.5% |
| Net profit (PAT) | 50 | 55 | -9.1% | 88 | -43.2% |
| EPS (₹) | 5.46 | 6.12 | -10.8% | 9.75 | -44% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹610 Cr, net profit ₹71 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aarti Pharmalabs Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aarti Pharmalabs Ltd Q1 FY26 results?
CDMO segment expected to grow 30%-40% this year, aiming for Rs. 800-1,000 crores revenue in 3-4 years (Page 17, 9). CDMO segment is expected to grow at 30%-40% annually this year, aiming for Rs. 800-1000 crore revenue in 3-4 years.
What is Aarti Pharmalabs Ltd share price analysis?
Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Pharmalabs Ltd planning capital expenditure?
Brownfield expansion to increase Xanthine derivatives capacity from 5,000 MT to 9,000 MT per annum; commissioning to be done in a phased manner across H2 FY '26.
Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
